[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601496":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":51,"id":57,"slug":58,"hasResults":59,"nctId":60,"briefTitle":61,"officialTitle":61,"acronym":20,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":66,"enrollmentInfo":67,"targetDuration":20,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},{"fullName":5,"class":6},"Oregon Health and Science University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Relugolix","EXPERIMENTAL","Participants will take Reugolix for 10 days starting at the midluteal time point (6-9 days after \"high fertility\" based on ovulation test)",[13],"Drug: Gonadotropin Releasing Hormone Antagonists Relugolix",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Gonadotropin Releasing Hormone Antagonists Relugolix","Gonadotropin releasing hormone antagonist (gnRH) taken for 10 days starting during the midluteal phase.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Leo Han, MD","PRINCIPAL_INVESTIGATOR",[26],{"name":27,"role":28,"phone":29,"phoneExt":20,"email":30},"Women's Health Research Unit Recruitment Line","CONTACT","503-494-3666","whru@ohsu.edu",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Oregon Health & Science University","RECRUITING","Portland","Oregon","97239","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-122.67621,45.52345,{"lat":44,"lon":43},[47],{"name":23,"role":28,"phone":20,"phoneExt":20,"email":20},{"type":24,"investigatorFullName":49,"investigatorTitle":50,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Leo Han","Principal Investigator",[52,55],{"name":53,"class":54},"National Institutes of Health (NIH)","NIH",{"name":56,"class":54},"Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","100601496","phase-4-insights-in-endocervical-mucus-secretion-100601496",false,"NCT07111247","Insights in Endocervical Mucus Secretion","Inclusion Criteria:\n\n* Normal menstrual cycles of 25-35 days in length for at least the previous 3 cycles\n* BMI \\>18 and \\\u003C35\n* Serum p4 \\>= 3 ng\u002Fml on single sample collected between days 18-25 of self-reported menstrual cycle\n* Flexible schedule allowing blood draws on less than 48 hour notice\n* In good general health\n* Commit to using non-hormonal contraceptive methods without spermicide during study period except those prescribed in the experimental protocol\n* No objections to taking study drugs\n* No objections to refraining from intercourse the night before any sampling and willing to use condoms during vaginal intercourse\n\nExclusion Criteria:\n\n* Oral contraceptive use or other hormone supplement within the preceding 2 months\n* Current cervical infection\n* Evidence of abnormal cervical cytology\n* Use of any IUD for contraception\n* Long-acting hormonal contraceptive use in the past 12 months (e.g., Depo-Provera)\n* Contraindications to study drugs\n* Current or past pregnancy within the previous 6 months or currently trying to conceive\n* Desiring to conceive in the next 8 months\n* Breastfeeding in the past 2 months\n* Diagnosed diabetes or metabolic syndrome\n* Diagnosed Polycystic Ovary Syndrome\n* History of, or self-reported, substance abuse\n* Smoker\n* Previous infertility treatment excluding male factor issues\n* Use of an investigational drug within the past 2 months\n* History of excisional or ablative treatment procedure on cervix (i.e., LEEP, Cryotherapy, Cold Knife Cone)\n* Current treatment for a vaginal infection such as bacterial vaginosis\n* History of venous thromboembolism (VTE) or inherited thrombophilias",true,"FEMALE","21 Years","40 Years",{"count":68,"type":69},15,"ESTIMATED","INTERVENTIONAL",[72],"PHASE4","Single arm interventional study looking at biological outcomes at 4 time points throughout the cycle before and after taking an oral gonadotropin-releasing hormone antagonist (gnRH). Samples of whole blood, endocervical mucus, endocervical biopsy, and vaginal swab will be collected.",[75],"Cervical Mucus","2026-01-06",{"date":78,"type":79},"2026-01-08","ACTUAL",{"date":81,"type":79},"2026-01-02",{"date":83,"type":69},"2027-08",{"name":5,"class":6},1]